- Jul 30, 2007
- 8,340
- 64
- 0
- School/Org
- Newsbot U
- City
- Barre
- State
- VT
Bayer HealthCare And Regeneron Initiate Phase 3 Global Development Program For VEGF Trap-Eye In Wet Age-Related Macular ... (Medical News Today)
Published: Mon, 06 Aug 2007 08:14:20 GMT
Bayer HealthCare AG and Regeneron Pharmaceuticals, Inc. announced today that the companies have initiated a Phase 3 study of the VEGF Trap-Eye in the neovascular form of age-related macular degeneration (wet AMD). The study will be a non-inferiority comparison of the VEGF Trap-Eye and ranibizumab (Lucentis®, a registered trademark of Genentech, Inc. [click link for full article]
Read More...
Published: Mon, 06 Aug 2007 08:14:20 GMT
Bayer HealthCare AG and Regeneron Pharmaceuticals, Inc. announced today that the companies have initiated a Phase 3 study of the VEGF Trap-Eye in the neovascular form of age-related macular degeneration (wet AMD). The study will be a non-inferiority comparison of the VEGF Trap-Eye and ranibizumab (Lucentis®, a registered trademark of Genentech, Inc. [click link for full article]
Read More...
